Skip to Content

Kyprolis Side Effects

Generic Name: carfilzomib

Note: This document contains side effect information about carfilzomib. Some of the dosage forms listed on this page may not apply to the brand name Kyprolis.

In Summary

Common side effects of Kyprolis include: asthenia, arthralgia, dyspnea, fever, thrombocytopenia, vomiting, and chills. Other side effects include: congestive heart failure, pulmonary edema, and reduced ejection fraction. See below for a comprehensive list of adverse effects.

For the Consumer

Applies to carfilzomib: intravenous powder for solution

Along with its needed effects, carfilzomib (the active ingredient contained in Kyprolis) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor or nurse immediately if any of the following side effects occur while taking carfilzomib:

More common

  • Agitation
  • black, tarry stools
  • bleeding gums
  • bloating or swelling of the face, arms, hands, lower legs, or feet
  • blood in the urine or stools
  • blurred vision
  • burning, crawling, itching, numbness, prickling, "pins and needles", or tingling feelings
  • chest pain
  • coma
  • confusion
  • cough or hoarseness
  • decreased urine output
  • depression
  • difficult or labored breathing
  • difficulty with moving
  • dizziness
  • drowsiness
  • fast, slow, or irregular heartbeat
  • headache
  • hostility
  • irregular heartbeat
  • irritability
  • lower back or side pain
  • muscle spasms (tetany) or twitching
  • nausea or vomiting
  • numbness or tingling in the hands, feet, or lips
  • painful or difficult urination
  • pale skin
  • pinpoint red spots on the skin
  • pounding in the ears
  • rapid weight gain
  • seizures
  • stupor
  • tightness in the chest
  • tingling of the hands or feet
  • trembling
  • troubled breathing with exertion
  • ulcers, sores, or white spots in the mouth
  • unsteadiness or awkwardness
  • unusual bleeding or bruising
  • unusual drowsiness, dullness, tiredness, weakness, or feeling of sluggishness
  • unusual tiredness or weakness
  • unusual weight gain or loss

Less common

  • Chills
  • fever
  • muscle pain or cramps
  • painful blisters on the trunk of the body
  • weakness in the arms, hands, legs, or feet

Rare

  • Dark-colored urine
  • general feeling of discomfort or illness
  • general feeling of tiredness or weakness
  • light-colored stools
  • stomach pain, continuing
  • thickening of bronchial secretions
  • yellow eyes or skin

Incidence not known

  • Blindness
  • dizziness, faintness, or lightheadedness when getting up suddenly from a lying or sitting position
  • fainting
  • joint pain, stiffness, or swelling
  • stomach pain
  • sweating

Some side effects of carfilzomib may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More common

For Healthcare Professionals

Applies to carfilzomib: intravenous powder for injection

Hematologic

Very common (10% or more): Anemia (47%), thrombocytopenia (36%), lymphopenia (24%), neutropenia (21%), leukopenia (14%)
Common (1% to 10%): Deep vein thrombosis
Uncommon (0.1% to 1%): Hemolytic uremic syndrome (HUS)
Rare (less than 0.1%): Thrombotic thrombocytopenic purpura (TTP), thrombotic microangiopathy, hemorrhage[Ref]

Cardiovascular

Very common (10% or more): Hypertension (14%)
Common (1% to 10%): Cardiac failure (i.e., pulmonary edema, decreased ejection fraction), atrial fibrillation, tachycardia, palpitations, flushing
Uncommon (0.1% to 1%): Cardiac arrest, myocardial infarction, myocardial ischemia, pericarditis, pericardial effusion
Rare (less than 0.1%): Hypertensive crisis[Ref]

Hepatic

Very common (10% or more): Increased aspartate aminotransferase (13%)
Common (1% to 10%): Increased alanine aminotransferase, increased gamma-glutamyltransferase, hyperbilirubinemia
Uncommon (0.1% to 1%): Hepatic failure, cholestasis[Ref]

Nervous system

Very common (10% or more): Headache (28%), peripheral neuropathy (14%), dizziness (13%), hypoesthesia (12%), dizziness
Postmarketing reports: Posterior reversible encephalopathy syndrome, paresthesia, hypoesthesia
Uncommon (0.1% to 1%): Intracranial hemorrhage, cerebrovascular accident
Rare (less than 0.1%): Posterior reversible encephalopathy syndrome (PRES)[Ref]

Other

Very common (10% or more): Fatigue (56%), pyrexia (30%), peripheral edema (24%), chills (16%), arthralgia (16%), asthenia (14%), pain (12%), infusion reaction
Common (1% to 10%): Dysphonia
Uncommon (0.1% to 1%): Multi-organ failure[Ref]

Respiratory

Very common (10% or more): Dyspnea (35%), upper respiratory tract infection (28%), cough (26%), pneumonia (13%), nasopharyngitis
Common (1% to 10%): Pulmonary hypertension, bronchitis, pulmonary embolism, pulmonary edema, epistaxis, rhinitis, wheezing
Uncommon (0.1% to 1%): Lung infection
Rare (less than 0.1%): Acute respiratory distress syndrome (ARDS), acute respiratory failure, pulmonary hemorrhage, interstitial lung disease, pneumonitis[Ref]

Gastrointestinal

Very common (10% or more): Nausea (45%), diarrhea (33%), vomiting (22%), constipation (21%), abdominal pain
Common (1% to 10%): Oropharyngeal pain, dyspepsia, toothache
Rare (less than 0.1%): GI hemorrhage, GI perforation[Ref]

Renal

Very common (10% or more): Increased blood creatinine (24%)
Common (1% to 10%): Acute renal failure, renal failure, renal impairment, decreased creatinine renal clearance[Ref]

Metabolic

Very common (10% or more): Hypokalemia (14%), hypomagnesemia (14%), anorexia (12%), hyperglycemia (12%), hypercalcemia (11%), hypophosphatemia (11%), hyponatremia (10%)
Common (1% to 10%): Dehydration, hyperkalemia, hypocalcemia, hyperuricemia, hypoalbuminemia
Uncommon (0.1% to 1%): Tumor lysis syndrome[Ref]

Musculoskeletal

Very common (10% or more): Back pain (20%), extremity pain (13%), chest wall pain (11%), arthralgia, muscle spasms
Common (1% to 10%): Musculoskeletal pain, musculoskeletal chest pain, bone pain, myalgia, muscular weakness[Ref]

Psychiatric

Very common (10% or more): Insomnia (17.9%)
Common (1% to 10%): Anxiety[Ref]

Immunologic

Common (1% to 10%): Herpes zoster reactivation, sepsis, influenza, viral infection[Ref]

Dermatologic

Common (1% to 10%): Rash, pruritus, erythema, hyperhidrosis[Ref]

Genitourinary

Common (1% to 10%): Urinary tract infection[Ref]

Hypersensitivity

Uncommon (0.1% to 1%): Drug hypersensitivity[Ref]

Ocular

Common (1% to 10%): Cataract, blurred vision
Frequency not reported: Blindness and other adverse visual disturbances (due to PRES)[Ref]

References

1. "Product Information. Kyprolis (carfilzomib)." Onyx Pharmaceuticals Inc, South San Francisco, CA.

2. Cerner Multum, Inc. "Australian Product Information." O 0

3. Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.

Hide